A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

Phase

1/2

Condition

Gaucher Disease

Anemia

Treatment

LY-M001

LY-M001 injection

Clinical Study ID

NCT06818838

LY-M001-GD-101

Ages 18-60
All Genders

Study Summary

Gaucher disease (GD) is caused by mutations in the GBA1 gene, which leads to a lack or reduction of GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate, Glucosylceramide (GlcCer), in macrophages in the liver, spleen, kidney, bone, lung, and even the brain, inducing their transformation into Gaucher cells whose cell cytoplasm presenting a characteristic "crumpled tissue paper" appearance, leading to pathological changes in involved tissues and organs.LY-M001 Injection is an rAAV8 vector gene therapy product. It can specifically transduce the target organ liver after a single intravenous administration and express the GCase protein in liver cells for a long period of time.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age ≥ 18 years and ≤ 60 years, male or female.
The subjects should fully understand the purpose, nature, and method of this studyas well as possible adverse reactions, and sign the informed consent form (ICF)voluntarily.
Patients with confirmed double mutations in the GBA1 allele through laboratorytesting, and the glucocerebrosidase activity was reduced to less than 30% of thenormal value(For example, the result of the dried blood spot (DBS) method is < 1.19 μmol/L/h), and meeting the standard clinical diagnosis criteria for GD1.
Patients who meet a) or b) below:
Treated patients with Gaucher disease type I who had previously received enzymereplacement therapy (ERT) or substrate clearance therapy (SRT) with GD, were onstable medication, eluted 5 drugs for a half-life or more beforeadministration, or were comprehensively judged to be stable by theinvestigator.
Newly treated or untreated GD1 patients who meet one or more of the followingcriteria at screening:

Hemoglobin ≥80g/L and less than the lower limit of normal;
Platelets ≥40×10^9/L and less than the lower limit of normal;
Hepatomegaly;
Splenomegaly.

Negative pregnancy test for female subjects of childbearing potential (WOCBP).Notes: WOCBP is defined as the absence of postmenopausal status (continuousamenorrhea of at least 12 months with no identifiable cause other than menopause),and the absence of surgical (i.e., ovarian, salpingectomy, and/or hysterectomy) orInvestigator-determined cause of permanent infertility due to other causes (e.g.,lenticular hypoplasia) after menarche in female subjects.
Subjects and their partners have no childbearing plans from the screening period to 6 months after the end of the study, and voluntarily adopt effective contraceptivemeasures (e.g., abstinence, condoms, etc.); subjects have no plans to donate spermor eggs.
Subjects are not to donate blood during the study and for at least 1 year after theend of the study.

Exclusion

Exclusion Criteria:

AAV8 neutralizing antibody positive (Antibody titer > 1:40).
Patients with clinically diagnosed Gaucher disease type II or III (GD2 or GD3).
Active and progressive bone disease that is expected to require surgical treatmentwithin the next 6 months.
Subject has idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenicpurpura (TTP), thrombocytopenia, anemia, hepatomegaly, splenomegaly, and/orosteoporosis unrelated to GD as judged by the Investigator.
Treatment or disposal of investigational drugs or investigational devices receivedin other clinical studies within 28 days prior to screening or within 5 half-lives (drugs only), whichever is older.
Evidence of clinically significant liver disease, fragile liver, or history ofexposure to hepatotoxins that meets, but is not limited to, any of the following atthe time of screening:

Progressive hepatomegaly larger than 3 times the normal volume.
History of stage 2 or above liver fibrosis.
AST, ALT, or TBIL are 1.5 times higher than ULN.
A history of alcohol or drug abuse within the previous 2 years (defined ashaving consumed more than 14 standard units of alcohol per week [1 standardunit containing 14 g of alcohol, such as 360 mL beer, 45 mL spirits containing 40% or more alcohol, or 150 mL wine]).
Hepatitis B surface antigen (HBsAg) positive and HBV deoxyribonucleic acid (HBV-DNA) positive (HBV-DNA>10^3 copy number /mL); Or take hepatitis B drugs (such as interferon, lamivudine, adefovir and entecavir); Or antibodies tohepatitis C virus (HCV) and positive for hepatitis C virus RNA.

Human immunodeficiency virus (HIV) antibody positive or Treponema pallidum antibodypositive.
Severe hyperlipidemia (triglycerides > 11.29mol/L).
Uncontrolled concomitant or infectious diseases (need to be determined by theinvestigator based on clinical practice).
The subject has received or plans to receive bone marrow transplantation,hematopoietic stem cell transplantation and/or major organ transplantation,including but not limited to liver transplantation, kidney transplantation, etc.
Subject has received erythropoietin, transfusion, or red blood cell transfusionwithin 3 months prior to screening; or platelet transfusion within 1 month prior toscreening.
Clinically diagnosed or investigator-determined serious cardiovascular disease (suchas heart failure ≥3 from the New York College of Cardiology [NYHA]).
Hypersensitivity to any component of LY-M001 injection.
Previous treatment with any type of gene therapy or cell therapy.
Use of systemic immunosuppressive agents or steroid therapy other than thoserequired by the protocol for prophylactic administration within 3 months prior todosing.
History of cancer within 5 years prior to screening, or currently active neoplasticdisease, except for basal or squamous cell carcinoma of the skin or carcinoma insitu that has been definitively treated.
Has received a live attenuated vaccine within 4 months prior to screening or plansto receive a live attenuated vaccine during the clinical trial.

6 months after the end of the study, and voluntarily adopt effective contraceptivemeasures (e.g., abstinence, condoms, etc.); subjects have no plans to donate spermor eggs.  7. Subjects are not to donate blood during the study and for at least 1 year after theend of the study.  Exclusion Criteria: 

AAV8 neutralizing antibody positive (Antibody titer > 1:40). 
Patients with clinically diagnosed Gaucher disease type II or III (GD2 or GD3). 
Active and progressive bone disease that is expected to require surgical treatmentwithin the next 6 months. 
Subject has idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenicpurpura (TTP), thrombocytopenia, anemia, hepatomegaly, splenomegaly, and/orosteoporosis unrelated to GD as judged by the Investigator. 
Treatment or disposal of investigational drugs or investigational devices receivedin other clinical studies within 28 days prior to screening or within 5 half-lives (drugs only), whichever is older. 
Evidence of clinically significant liver disease, fragile liver, or history ofexposure to hepatotoxins that meets, but is not limited to, any of the following atthe time of screening:

Progressive hepatomegaly larger than 3 times the normal volume. 
History of stage 2 or above liver fibrosis. 
AST, ALT, or TBIL are 1.5 times higher than ULN. 
A history of alcohol or drug abuse within the previous 2 years (defined ashaving consumed more than 14 standard units of alcohol per week [1 standardunit containing 14 g of alcohol, such as 360 mL beer, 45 mL spirits containing 40% or more alcohol, or 150 mL wine]). 
Hepatitis B surface antigen (HBsAg) positive and HBV deoxyribonucleic acid (HBV-DNA) positive (HBV-DNA>10^3 copy number /mL); Or take hepatitis B drugs (such as interferon, lamivudine, adefovir and entecavir); Or antibodies tohepatitis C virus (HCV) and positive for hepatitis C virus RNA.

Human immunodeficiency virus (HIV) antibody positive or Treponema pallidum antibodypositive. 
Severe hyperlipidemia (triglycerides > 11.29mol/L). 
Uncontrolled concomitant or infectious diseases (need to be determined by theinvestigator based on clinical practice). 
The subject has received or plans to receive bone marrow transplantation,hematopoietic stem cell transplantation and/or major organ transplantation,including but not limited to liver transplantation, kidney transplantation, etc. 
Subject has received erythropoietin, transfusion, or red blood cell transfusionwithin 3 months prior to screening; or platelet transfusion within 1 month prior toscreening. 
Clinically diagnosed or investigator-determined serious cardiovascular disease (suchas heart failure ≥3 from the New York College of Cardiology [NYHA]). 
Hypersensitivity to any component of LY-M001 injection. 
Previous treatment with any type of gene therapy or cell therapy. 
Use of systemic immunosuppressive agents or steroid therapy other than thoserequired by the protocol for prophylactic administration within 3 months prior todosing. 
History of cancer within 5 years prior to screening, or currently active neoplasticdisease, except for basal or squamous cell carcinoma of the skin or carcinoma insitu that has been definitively treated. 
Has received a live attenuated vaccine within 4 months prior to screening or plansto receive a live attenuated vaccine during the clinical trial. 
Other conditions that, in the opinion of the Investigator, make the subjectunsuitable for the study.

Study Design

LY-M001

1/2

July 05, 2024

July 30, 2031

Study Description

The purpose of this study is to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacokinetics of LY-M001 injection in patients with GD1 using a multicenter, open, single-arm, single-dose, dose-escalation and extended clinical design. This study includes the main study phase and the long-term follow-up study phase. The primary study period is 52 weeks after LY-M001 infusion, and the long-term follow-up period is 53 weeks to 5 years after LY-M001 infusion.Subjects who complete the 52 weeks follow up period or who prematurely withdraw in this study will enter the long-term follow-up study phase to obtain long-term assessment data.

Phase I is a dose escalation study consists of three preset dose groups, including one rollback dose group and two incremental dose groups, which are: Backdose (5 × 10^12 vg/kg) group, dose group 1 (1.5 × 10^13 vg/kg) and dose group 2 (3.0 × 10^13 vg/kg), where dose group 1 was the starting dose of the Phase I study. Three subjects are enrolled in each dose group one by one, and each subject is added to the next subject after at least 28 days of DLT observation to determine safety. Phase I studies enrolled approximately 6 to 12 (up to 12) evaluable subjects.

Phase II is a dose expansion study. After all subjects in Phase I study have completed the Day 28 (D28) observation following LY-M001 infusion, the Recommended Phase 2 Dose (RP2D) will be determined by the Safety Review Committee (SRC), which will also decide whether to proceed to the dose-expansion Phase II study.

Connect with a study center

Guangzhou First People's Hospital
Guangzhou 1809858, Guangdong 1809935 510000
China
Active - Recruiting
Shanxi Bethune Hospital
Taiyuan 1793511, Shanxi 1795912 030000
China
Active - Recruiting
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin 1792947, Tianjin Municipality 1792943 300011
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.